Omid Hamid

List of Publications by Citations

63 papers	35,272 citations	40 h-index	64 g-index
64 ext. papers	41,668 ext. citations	15 avg, IF	6.5 L-index

#	Paper	IF	Citations
63	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *New England Journal of Medicine*, **2012**, 366, 2455-65	59.2	5527
62	Pembrolizumab for the treatment of non-small-cell lung cancer. *New England Journal of Medicine*, **2015**, 372, 2018-28	59.2	3943
61	Pembrolizumab versus Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2015**, 372, 2521-32	59.2	3792
60	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* , **2014**, 515, 563-7	50.4	3354
59	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *New England Journal of Medicine*, **2013**, 369, 134-44	59.2	2661
58	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clinical Cancer Research*, **2009**, 15, 7412-20	12.9	2380
57	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *Journal of Clinical Oncology*, **2015**, 33, 1889-94	2.2	1425
56	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet, The*, **2014**, 384, 1109-17	40	1340
55	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 908-18	21.7	1151
54	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *New England Journal of Medicine*, **2016**, 375, 1845-1855	59.2	870
53	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 522-30	21.7	842
52	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet, The*, **2017**, 390, 1853-1862	40	703
51	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1600-9	27.4	666
50	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *New England Journal of Medicine*, **2018**, 379, 722-730	59.2	659
49	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3119-25	2.2	601
48	An immune-active tumor microenvironment favors clinical response to ipilimumab. *Cancer Immunology, Immunotherapy*, **2012**, 61, 1019-31	7.4	562
47	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. *Journal of Clinical Oncology*, **2016**, 34, 1510-7	2.2	509

46	A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. *Clinical Cancer Research*, **2009**, 15, 5591-8	12.9	457
45	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncology, The*, **2019**, 20, 1239-1251	21.7	425
44	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. *Journal of Clinical Oncology*, **2016**, 34, 833-42	2.2	420
43	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. *Journal of Translational Medicine*, **2011**, 9, 204	8.5	412
42	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. *Journal of Clinical Oncology*, **2015**, 33, 4023-31	2.2	315
41	Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. *Cancer*, **2007**, 110, 2614-27	6.4	231
40	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. *Journal of Clinical Oncology*, **2016**, 34, 871-8	2.2	206
39	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. *Journal of Clinical Oncology*, **2014**, 32, 3697-704	2.2	158
38	Sunitinib therapy for melanoma patients with KIT mutations. *Clinical Cancer Research*, **2012**, 18, 1457-63	12.9	158
37	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. *Clinical Cancer Research*, **2018**, 24, 4960-4967	12.9	142
36	Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. *Journal of Clinical Oncology*, **2018**, 36, 667-673	2.2	138
35	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. *European Journal of Cancer*, **2017**, 86, 37-45	7.5	106
34	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. *Expert Opinion on Biological Therapy*, **2013**, 13, 847-61	5.4	96
33	Mucosal melanoma: pathogenesis, clinical behavior, and management. *Current Oncology Reports*, **2012**, 14, 441-8	6.3	93
32	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncology, The*, **2019**, 20, e378-e389	21.7	88
31	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. *European Journal of Cancer*, **2019**, 119, 1-10	7.5	79
30	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. *Cancer Immunity*, **2010**, 10, 9		78
29	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. *Cancer Immunology, Immunotherapy*, **2012**, 61, 733-7	7.4	71

28	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. *New England Journal of Medicine*, **2021**, 385, 1196-1206	59.2	63
27	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. *British Journal of Cancer*, **2018**, 119, 670-674	8.7	60
26	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. *European Journal of Cancer*, **2016**, 67, 46-54	7.5	54
25	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. *Clinical Cancer Research*, **2020**, 26, 5869-5878	12.9	50
24	Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. *Cancer Immunology, Immunotherapy*, **2017**, 66, 1249-1264	7.4	41
23	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. *Journal of Clinical Oncology*, **2021**, 39, 2656-2666	2.2	35
22	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. *Clinical Cancer Research*, **2019**, 25, 6061-6072	12.9	33
21	Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. *Frontiers in Oncology*, **2014**, 4, 110	5.3	33
20	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. *Journal of Clinical Oncology*, **2016**, 34, 9504-9504	2.2	32
19	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. *JAMA Oncology*, **2020**, 6, 1256-1264	13.4	27
18	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. *Clinical Cancer Research*, **2020**, 26, 4201-4205	12.9	25
17	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for -Mutant Melanoma. *Cancers*, **2019**, 11,	6.6	24
16	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. *Journal of Clinical Oncology*, **2018**, 36, 9516-9516	2.2	24
15	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. *European Journal of Cancer*, **2021**, 144, 182-191	7.5	23
14	Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. *Journal of Clinical Oncology*, **2015**, 33, 9063-9063	2.2	22
13	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. *Clinical Cancer Research*, **2020**, 26, 4531-4541	12.9	21
12	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. *Journal of Clinical Oncology*, **2012**, 30, 25-25	2.2	9
11	Improved survival in women versus men with merkel cell carcinoma. *Journal of the American Academy of Dermatology*, **2021**, 84, 321-329	4.5	8

List of Publications

10	A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. *Clinical Cancer Research*, **2021**,	12.9	7
9	Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients. *Cancer Research*, **2021**,	10.1	5
8	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. *Journal of the American Academy of Dermatology*, **2021**, 84, 312-320	4.5	5
7	The association between facility volume and overall survival in patients with Merkel cell carcinoma. *Journal of Surgical Oncology*, **2020**, 122, 254-262	2.8	4
6	P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies Independent review committee data update **2020**, 8, A12-A12		2
5	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. *European Journal of Cancer*, **2021**, 157, 391-402	7.5	2
4	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response. *Clinical Cancer Research*, **2020**, 26, 2436	12.9	1
3	Letter Regarding Editorial by Samuel Zagarella. *American Journal of Dermatopathology*, **2021**, 43, 539-540	0.9	1
2	Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC. *Journal of Thoracic Oncology*, **2017**, 12, 1857-1858	8.9	
1	The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. *Journal of Translational Medicine*, **2022**, 20, 179	8.5	